Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
999 Ganmaoling is a widely recognized over-the-counter (OTC) hybrid medication developed and marketed by CR Sanjiu for the symptomatic relief of the common cold and upper respiratory tract infections. The product is a 'hybrid' formulation, integrating Western pharmaceutical compounds—specifically acetaminophen (0.2g), caffeine (4mg), and chlorpheniramine maleate (4mg)—with a blend of traditional Chinese medicinal herbs including *Evodia lepta*, *Ilex asprella*, wild chrysanthemum, *Bidens pilosa*, and peppermint oil. This combination provides comprehensive relief from fever, headache, sore throat, nasal congestion, and runny nose. It is formulated as granules for oral administration, typically dissolved in hot water, and holds a formal drug approval in China (国药准字Z44021940).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 999 Ganmaoling.